Alectos Therapeutics Announces Collaboration with Merck to Develop Drugs for Alzheimer's Disease
13-Aug-2010 -
Alectos Therapeutics Inc. announced a research collaboration with Merck & Co., Inc. to identify and develop compounds that modulate O-linked N-acetylglucosaminidase (O-GlcNAcase) an enzyme that is believed to be involved in the development of Alzheimer's disease and potentially other disorders. ...
Alzheimer's disease
Merck
research collaborations